References
BEAL, M. F. 2010. Parkinson’s disease: a model dilemma. Nature,466, S8-10.
BERGER, A., LORAIN, S., JOSEPHINE, C., DESROSIERS, M., PECCATE, C.,
VOIT, T., GARCIA, L., SAHEL, J. A. & BEMELMANS, A. P. 2015. Repair of
rhodopsin mRNA by spliceosome-mediated RNA trans-splicing: a new
approach for autosomal dominant retinitis pigmentosa. Mol Ther,23, 918-930.
BEZARD, E. & PRZEDBORSKI, S. 2011. A tale on animal models of
Parkinson’s disease. Mov Disord, 26, 993-1002.
BJORKLUND, A., NILSSON, F., MATTSSON, B., HOBAN, D. B. & PARMAR, M.
2022. A Combined alpha-Synuclein/Fibril (SynFib) Model of Parkinson-Like
Synucleinopathy Targeting the Nigrostriatal Dopamine System. J
Parkinsons Dis, 12, 2307-2320.
BURRE, J. 2015. The Synaptic Function of alpha-Synuclein. J
Parkinsons Dis, 5, 699-713.
BURRE, J., SHARMA, M. & SUDHOF, T. C. 2018. Cell Biology and
Pathophysiology of alpha-Synuclein. Cold Spring Harb Perspect
Med, 8.
CEGELSKI, L., PINKNER, J. S., HAMMER, N. D., CUSUMANO, C. K., HUNG, C.
S., CHORELL, E., ABERG, V., WALKER, J. N., SEED, P. C., ALMQVIST, F.,
CHAPMAN, M. R. & HULTGREN, S. J. 2009. Small-molecule inhibitors target
Escherichia coli amyloid biogenesis and biofilm formation. Nat
Chem Biol, 5, 913-9.
CENCI, M. A. & BJORKLUND, A. 2020. Animal models for preclinical
Parkinson’s research: An update and critical appraisal. Prog Brain
Res, 252, 27-59.
CHERMENINA, M., CHORELL, E., POKRZYWA, M., ANTTI, H., ALMQVIST, F.,
STROMBERG, I. & WITTUNG-STAFSHEDE, P. 2015. Single injection of
small-molecule amyloid accelerator results in cell death of nigral
dopamine neurons in mice. NPJ Parkinsons Dis, 1, 15024.
DOWD, E., MONVILLE, C., TORRES, E. M. & DUNNETT, S. B. 2005. The
Corridor Task: a simple test of lateralised response selection sensitive
to unilateral dopamine deafferentation and graft-derived dopamine
replacement in the striatum. Brain Res Bull, 68, 24-30.
FITZSIMMONS, D. F., MOLONEY, T. C. & DOWD, E. 2006. Further validation
of the corridor task for assessing deficit and recovery in the
hemi-Parkinsonian rat: restoration of bilateral food retrieval by
dopamine receptor agonism. Behav Brain Res, 169, 352-5.
HORVATH, I., WEISE, C. F., ANDERSSON, E. K., CHORELL, E., SELLSTEDT, M.,
BENGTSSON, C., OLOFSSON, A., HULTGREN, S. J., CHAPMAN, M., WOLF-WATZ,
M., ALMQVIST, F. & WITTUNG-STAFSHEDE, P. 2012. Mechanisms of protein
oligomerization: inhibitor of functional amyloids templates
alpha-synuclein fibrillation. J Am Chem Soc, 134,3439-44.
KELLY, R., CAIRNS, A. G., ADEN, J., ALMQVIST, F., BEMELMANS, A. P.,
BROUILLET, E., PATTON, T., MCKERNAN, D. P. & DOWD, E. 2021. The Small
Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein
Pathology in Subclinical AAV Rat Models. Biomolecules, 11.
KIRIK, D., ANNETT, L. E., BURGER, C., MUZYCZKA, N., MANDEL, R. J. &
BJORKLUND, A. 2003. Nigrostriatal alpha-synucleinopathy induced by viral
vector-mediated overexpression of human alpha-synuclein: a new primate
model of Parkinson’s disease. Proc Natl Acad Sci U S A,100, 2884-9.
KIRIK, D., ROSENBLAD, C., BURGER, C., LUNDBERG, C., JOHANSEN, T. E.,
MUZYCZKA, N., MANDEL, R. J. & BJORKLUND, A. 2002. Parkinson-like
neurodegeneration induced by targeted overexpression of alpha-synuclein
in the nigrostriatal system. J Neurosci, 22, 2780-91.
LO BIANCO, C., RIDET, J. L., SCHNEIDER, B. L., DEGLON, N. & AEBISCHER,
P. 2002. alpha -Synucleinopathy and selective dopaminergic neuron loss
in a rat lentiviral-based model of Parkinson’s disease. Proc Natl
Acad Sci U S A, 99, 10813-8.
MURPHY, J. & MCKERNAN, D. P. 2022. The Effect of Aggregated Alpha
Synuclein on Synaptic and Axonal Proteins in Parkinson’s Disease-A
Systematic Review. Biomolecules, 12.
OLSEN, L. K., CAIRNS, A. G., ADEN, J., MORIARTY, N., CABRE, S.,
ALAMILLA, V. R., ALMQVIST, F., DOWD, E. & MCKERNAN, D. P. 2019. Viral
mimetic priming enhances alpha-synuclein-induced degeneration:
Implications for Parkinson’s disease. Brain Behav Immun,80, 525-535.
OLSSON, M., NIKKHAH, G., BENTLAGE, C. & BJORKLUND, A. 1995. Forelimb
akinesia in the rat Parkinson model: differential effects of dopamine
agonists and nigral transplants as assessed by a new stepping test.J Neurosci, 15, 3863-75.
OUESLATI, A. 2016. Implication of Alpha-Synuclein Phosphorylation at
S129 in Synucleinopathies: What Have We Learned in the Last Decade?J Parkinsons Dis, 6, 39-51.
POKRZYWA, M., PAWELEK, K., KUCIA, W. E., SARBAK, S., CHORELL, E.,
ALMQVIST, F. & WITTUNG-STAFSHEDE, P. 2017. Effects of small-molecule
amyloid modulators on a Drosophila model of Parkinson’s disease.PLoS One, 12, e0184117.
POLINSKI, N. K., VOLPICELLI-DALEY, L. A., SORTWELL, C. E., LUK, K. C.,
CREMADES, N., GOTTLER, L. M., FROULA, J., DUFFY, M. F., LEE, V. M. Y.,
MARTINEZ, T. N. & DAVE, K. D. 2018. Best Practices for Generating and
Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson’s Disease in
Rodents. J Parkinsons Dis, 8, 303-322.
SCHALLERT, T., FLEMING, S. M., LEASURE, J. L., TILLERSON, J. L. &
BLAND, S. T. 2000. CNS plasticity and assessment of forelimb
sensorimotor outcome in unilateral rat models of stroke, cortical
ablation, parkinsonism and spinal cord injury. Neuropharmacology,39, 777-87.
SHARMA, M. & BURRE, J. 2023. alpha-Synuclein in synaptic function and
dysfunction. Trends Neurosci, 46, 153-166.
SPILLANTINI, M. G., CROWTHER, R. A., JAKES, R., HASEGAWA, M. & GOEDERT,
M. 1998. alpha-Synuclein in filamentous inclusions of Lewy bodies from
Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad
Sci U S A, 95, 6469-73.
ST MARTIN, J. L., KLUCKEN, J., OUTEIRO, T. F., NGUYEN, P.,
KELLER-MCGANDY, C., CANTUTI-CASTELVETRI, I., GRAMMATOPOULOS, T. N.,
STANDAERT, D. G., HYMAN, B. T. & MCLEAN, P. J. 2007. Dopaminergic
neuron loss and up-regulation of chaperone protein mRNA induced by
targeted over-expression of alpha-synuclein in mouse substantia nigra.J Neurochem, 100, 1449-57.
TAGLIAFERRO, P. & BURKE, R. E. 2016. Retrograde Axonal Degeneration in
Parkinson Disease. J Parkinsons Dis, 6, 1-15.
THAKUR, P., BREGER, L. S., LUNDBLAD, M., WAN, O. W., MATTSSON, B., LUK,
K. C., LEE, V. M. Y., TROJANOWSKI, J. Q. & BJORKLUND, A. 2017. Modeling
Parkinson’s disease pathology by combination of fibril seeds and
alpha-synuclein overexpression in the rat brain. Proc Natl Acad
Sci U S A, 114, E8284-E8293.
TOFARIS, G. K. 2022. Initiation and progression of alpha-synuclein
pathology in Parkinson’s disease. Cell Mol Life Sci, 79,210.
TRIGO-DAMAS, I., DEL REY, N. L. & BLESA, J. 2018. Novel models for
Parkinson’s disease and their impact on future drug discovery.Expert Opin Drug Discov, 13, 229-239.
UCHIHARA, T. & GIASSON, B. I. 2016. Propagation of alpha-synuclein
pathology: hypotheses, discoveries, and yet unresolved questions from
experimental and human brain studies. Acta Neuropathol,131, 49-73.
VAN DER PERREN, A., TOELEN, J., CARLON, M., VAN DEN HAUTE, C., COUN, F.,
HEEMAN, B., REUMERS, V., VANDENBERGHE, L. H., WILSON, J. M., DEBYSER, Z.
& BAEKELANDT, V. 2011. Efficient and stable transduction of
dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5,
2/6.2, 2/7, 2/8 and 2/9. Gene Ther, 18, 517-27.
VAN DER PERREN, A., VAN DEN HAUTE, C. & BAEKELANDT, V. 2015. Viral
vector-based models of Parkinson’s disease. Curr Top Behav
Neurosci, 22, 271-301.
VOLPICELLI-DALEY, L. A., KIRIK, D., STOYKA, L. E., STANDAERT, D. G. &
HARMS, A. S. 2016. How can rAAV-alpha-synuclein and the fibril
alpha-synuclein models advance our understanding of Parkinson’s disease?J Neurochem, 139 Suppl 1, 131-155.
WONG, Y. C., LUK, K., PURTELL, K., BURKE NANNI, S., STOESSL, A. J.,
TRUDEAU, L. E., YUE, Z., KRAINC, D., OERTEL, W., OBESO, J. A. &
VOLPICELLI-DALEY, L. A. 2019. Neuronal vulnerability in Parkinson
disease: Should the focus be on axons and synaptic terminals? Mov
Disord, 34, 1406-1422.
XU, Y., DENG, Y. & QING, H. 2015. The phosphorylation of
alpha-synuclein: development and implication for the mechanism and
therapy of the Parkinson’s disease. J Neurochem, 135,4-18.